Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | ICMT | O60725 | 14/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 2/20 | 0.51 |
| ▸ | FNTB | P49356 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17399967 | 1.00 | MAPT (0.72) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL3420372 | 1.00 | MAPT (0.72) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL3420374 | 1.00 | MAPT (0.72) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL13367293 | 0.91 | MAPT (0.72) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL13274239 | 0.86 | MAPT (0.62) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL14328063 | 0.85 | MAPT (0.77) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL1814594 | 0.85 | MAPT (0.77) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL18298108 | 0.85 | MAPT (0.77) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL21697764 | 0.85 | MAPT (0.77) | MAPTALDH1A1ICMTMEN1TRPA1 | |
| SCHEMBL1814592 | 0.85 | MAPT (0.77) | MAPTALDH1A1ICMTMEN1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3330252-B1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | SIGNUM BIOSCIENCES INC (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3330252-B1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | SIGNUM BIOSCIENCES INC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10314802-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10314802-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| EP-3330252-A2 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | Signum Biosciences, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-3330252-A2 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | Signum Biosciences, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| US-20170368011-A1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | SIGNUM BIOSCIENCES, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-9744147-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9744147-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9744147-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20130310559-A1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | SIGNUM BIOSCIENCES, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130310559-A1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | SIGNUM BIOSCIENCES, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8372884-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. | 2013-02-12 | — | — | US | disclosed |
| US-8372884-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. | 2013-02-12 | — | — | US | disclosed |
| US-8372884-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. | 2013-02-12 | — | — | US | disclosed |
| US-20100247461-A1 | ANTI-INFLAMMATORY COMPLEXES | SIGNUM BIOSCIENCES, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100184768-A1 | Isoprenyl Compounds and Methods Thereof | SIGNUM BIOSCIENCES, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184768-A1 | Isoprenyl Compounds and Methods Thereof | SIGNUM BIOSCIENCES, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184768-A1 | Isoprenyl Compounds and Methods Thereof | SIGNUM BIOSCIENCES, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010056778-A1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | SIGNUM BIOSCIENCES, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184768-A1 | Isoprenyl Compounds and Methods Thereof | ALOX15B, ALOX15, ALOX5 | MAPT 4014/4885ALDH1A1 882/4885ICMT 267/4885 |
| US-10314802-B2 | Isoprenyl compounds and methods thereof | ALOX15B, ALOX15, ALOX5 | MAPT 4014/4885ALDH1A1 882/4885ICMT 267/4885 |
| US-20130310559-A1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | ALOX15B, ALOX15, ALOX5 | MAPT 4014/4885ALDH1A1 882/4885ICMT 267/4885 |
| US-20170368011-A1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | ALOX15B, ALOX15, ALOX5 | MAPT 4014/4885ALDH1A1 882/4885ICMT 267/4885 |
| US-20100247461-A1 | ANTI-INFLAMMATORY COMPLEXES | SSB, NFKBIA, FABP1 | MAPT 2899/4885ALDH1A1 1904/4885ICMT 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.